ETC

Recommend
Index
  • Solian Tab. 400mg

    Solian Tab. 400mg

    Ingredient

    Amisulpride

    Content

    400mg

    Indication

    Treatment of schizophrenia

  • Stilnox CR Tab. 12.5mg

    Stilnox CR Tab. 12.5mg

    Ingredient

    Zolpidem Tartrate

    Content

    12.5mg

    Indication

    Short-term treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.

  • Stilnox CR Tab. 6.25mg

    Stilnox CR Tab. 6.25mg

    Ingredient

    Zolpidem Tartrate

    Content

    6.25mg

    Indication

    Short-term treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.

  • Stilnox Tab. 10mg

    Stilnox Tab. 10mg

    Ingredient

    Zolpidem Tartrate

    Content

    10mg

    Indication

    Short-term treatment of insomnia in adults

  • Strensiq

    Strensiq

    Ingredient

    Asfotase-alfa

    Content

    18 mg/0.45 mL, 28 mg/0.7 mL, 40 mg/mL, or 80 mg/0.8 mL solution in single-dose vials

    Indication

    Long-term enzyme replacement therapy in patients with pediatric-onset hypophosphatasia to treat the bone manifestations of the disease. Pediatric includes perinatal/infantile (0-6 months of age at the time of onset) and juvenile (6 months to 18 years of age at the time of onset).

  • Suglat<sup>®</sup>Tablet 50mg

    Suglat®Tablet 50mg

    Ingredient

    Ipragliflozin L-proline (In-house spec.) 64.3mg (50 mg as Ipragliflozin)

    Content

    Light purple, round, film-coated tablet

    Indication

    This drug is administered as an adjunct to diet and exercise to improve the glucose control of patients with type 2 diabetes.
    – Monotherapy
    – Combination therapy

  • Telmidiqual<sup>®</sup>

    Telmidiqual®

    Ingredient

    Telmisartan/ Amlodipine

    Content

    40/5mg 40/10mg 80/5mg

    Indication

    Treatment of essential hypertension.

    Telmidiqual is indicated in adult patients whose blood pressure is not adequately controlled on Telmisartan or Amlodipine monotherapy

  • Tenelia M SR Tab. 10/500mg

    Tenelia M SR Tab. 10/500mg

    Ingredient

    Teneligliptin Hydrobromide Hydrate/Metformin Hydrochloride

    Content

    Teneligliptin Hydrobromide Hydrate 15.5mg (10mg as Teneligliptin), Metformin Hydrochloride 500mg

    Indication

    This drug is administered as an adjunct to diet and exercise to improve the glucose control of patients with type 2 diabetes who are adequate to combination therapy of teneligliptin and metformin.

  • Tenelia M SR Tab. 10/750mg

    Tenelia M SR Tab. 10/750mg

    Ingredient

    Teneligliptin Hydrobromide Hydrate/Metformin Hydrochloride

    Content

    Teneligliptin Hydrobromide Hydrate 15.5mg (10mg as Teneligliptin), Metformin Hydrochloride 750mg

    Indication

    This drug is administered as an adjunct to diet and exercise to improve the glucose control of patients with type 2 diabetes who are adequate to combination therapy of teneligliptin and metformin.

  • Tenelia M SR Tab. 20/1000mg

    Tenelia M SR Tab. 20/1000mg

    Ingredient

    Teneligliptin Hydrobromide Hydrate/Metformin Hydrochloride

    Content

    Teneligliptin Hydrobromide Hydrate 31mg (20mg as Teneligliptin), Metformin Hydrochloride 1000mg

    Indication

    This drug is administered as an adjunct to diet and exercise to improve the glucose control of patients with type 2 diabetes who are adequate to combination therapy of teneligliptin and metformin.

TOP